Docetaxel + prednisone
Checked 2026-09-09
Metastatic hormone-sensitive (with ADT, 6 cycles: CHAARTED, ARASENS) or castration-resistant prostate cancer
One cycle
every 21 days × 6 · about 18 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Docetaxel Cytotoxic chemotherapy (taxane) | 75 mg/m² | IV | D1 | |
Prednisone | 5 mg twice daily | Oral | D1-21 |
Cycles
6 (hormone-sensitive); up to 10 (castration-resistant)
21-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Consider (10-20% FN risk)
Notes
- ARASENS adds darolutamide 600 mg twice daily; PEACE-1 adds abiraterone.
Used in
Products
Source
TAX 327, NEJM 2004; CHAARTED, NEJM 2015
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Cabazitaxel + prednisone
Metastatic castration-resistant prostate cancer after docetaxel and an AR-pathway inhibitor
every 21 days
Abiraterone + prednisone with ADT
High-risk metastatic hormone-sensitive (LATITUDE, STAMPEDE) or castration-resistant prostate cancer
every 28 days
177Lu-PSMA-617
PSMA PET-positive metastatic castration-resistant prostate cancer after an AR-pathway inhibitor (PSMAfore) and, in VISION, after taxane
every 42 days × 6
Olaparib maintenance
Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum
every 28 days × 2